BIOPHARMA CREDIT PLC

Declaration of Voting Results & Voting Rights Announcements • May 30, 2023

National Storage Mechanism | Additional information

RNS Number : 0607B

BioPharma Credit PLC

30 May 2023

BIOPHARMA CREDIT PLC

(THE "COMPANY")

RESULT OF 2023 ANNUAL GENERAL MEETING

The Company is pleased to announce that, at the Annual General Meeting held today, all resolutions put to the meeting were passed by way of a poll.

Resolutions	Votes For	%	Votes Against	%	Votes Withheld1
1: To receive and accept the annual report and financial statements	584,028,016	100.00%	0	0.00%	0
2: To approve the Directors' Remuneration Report	583,832,967	99.98%	132,056	0.02%	62,993
3: To re-elect Harry Hyman as a Director	509,140,483	87.18%	74,848,533	12.82%	39,000
4: To re-elect Colin Bond as a Director	583,961,133	100.00%	22,183	0.00%	44,700
5: To re-elect Duncan Budge as a Director	506,318,657	86.70%	77,664,659	13.30%	44,700
6: To re-elect Stephanie Léouzon as a Director	583,960,840	100.00%	22,476	0.00%	44,700
7: To re-elect Rolf Soderstrom as a Director	583,977,236	100.00%	6,080	0.00%	44,700
8: To elect Sapna Shah as a Director	583,973,133	100.00%	8,683	0.00%	46,200
9: To re-appoint Ernst & Young LLP as Auditor to the Company	572,909,389	98.10%	11,112,627	1.90%	6,000
10: To authorise the Directors to determine the remuneration of the Auditor	583,954,933	100.00%	20,060	0.00%	53,023
11: To approve the Company's dividend payment policy	573,028,016	98.12%	11,000,000	1.88%	0
12: To authorise the allotment of shares by the Company	582,922,005	100.00%	25,280	0.00%	1,080,731
13: To authorise the disapplication of pre-emption rights	556,590,025	95.48%	26,367,212	4.52%	1,070,779
14: To authorise the Company to make market purchases of ordinary shares	509,047,631	87.32%	73,929,283	12.68%	1,051,102
15: To authorise the Company to hold general meetings on 14 clear days' notice	583,949,781	99.99%	78,235	0.01%	0

1.     A 'vote withheld' is not a vote under English law and is not counted in the calculation of votes 'for' or 'against' a resolution.

Copies of resolutions 12 to 15 have been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

30 May 2023

Enquiries

BioPharma Credit plc

via Link Company Matters Limited

Company Secretary

T. +44 (0) 333 300 1950  

Buchanan

David Rydell / Mark Court / Jamie Hooper / Henry Wilson

+44 (0) 20 7466 5000

biopharmacredit@buchanan.uk.com

Notes to Editors:

BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

LEI: 213800AV55PYXAS7SY24

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGSDMFLSEDSESI